Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer

Objective: To evaluate the efficacy and treatment rationale of Hürthle cell carcinoma (HCC) following a patient with progressive and metastatic HCC. HCC was recently shown to harbor a distinct genetic make-up and the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kiase (PI3K)/AKT...

Descripción completa

Detalles Bibliográficos
Autores principales: Aydemirli, Mehtap Derya, Corver, Willem, Beuk, Ruben, Roepman, Paul, Solleveld-Westerink, Nienke, van Wezel, Tom, Kapiteijn, Ellen, Morreau, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721552/
https://www.ncbi.nlm.nih.gov/pubmed/31443247
http://dx.doi.org/10.3390/cancers11081185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721552/
https://www.ncbi.nlm.nih.gov/pubmed/31443247
http://dx.doi.org/10.3390/cancers11081185

Ejemplares similares